Eagle Pharmaceuticals
As of the edition of 20 October 2026, Eagle Pharmaceuticals runs 6 drugs, 5 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Status not established | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Docetaxel anhydrous | none listed | 0 |
| Pemetrexed | none listed | 7 |
| Bendamustine | Ends 2029 (patent) | 0 |
| Argatroban | none listed | 1 |
| Dantrolene | none listed | 2 |
A route B row is one company at one target.
Where its trials are
- Infections: 1 trials led
- Lungs and airways: 1 trials led